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1      INTRODUCTION AND OBJECTIVE OF THE STUDY 
 
1.1       Diabetes mellitus 
 
1.1.1 Definition and history 
Diabetes mellitus (DM) comprises a group of common metabolic disorders of multiple 
aetiologies that share the phenotype of hyperglycaemia together with disturbances of 
carbohydrate, fat and protein metabolism resulting from defects of insulin secretion, insulin 
action or both. Chronically elevated blood glucose (BG) concentrations give rise to its main 
symptom of passing large quantities of sweet-tasting urine (diabetes from the Greek word 
meaning ‘a siphon’, as the body acts as a conduit for the excess fluid, and mellitus from the 
Greek and Latin for honey)
1
.  
The characteristic clinical presentation is thirst, polyuria, blurring of vision and weight loss. 
Often, symptoms are mild or absent and mild hyperglycaemia can persist for years with tissue 
damage developing, although the person may be totally asymptomatic. 
It is the complications of diabetes which make it a major public health problem. Absolute 
deficiency of insulin leads to ketoacidosis and coma with a considerable mortality. 
Hyperglycaemic hyperosmolar state is even more common and serious in elderly people with 
type 2 diabetes and comorbidities
 1,2
. 
Long term hyperglycaemia affects the microvasculature of the kidney, eye and nerve as well 
as the large arteries, leading to atherosclerosis. Diabetes is the most common single cause of 
end-stage renal failure, the most common cause of blindness of working age, and the 
consequences of neuropathy make it the most common cause of non-traumatic lower limb 
amputation. Mortality from ischaemic heart disease and stroke is 2-4-fold higher than in non-
diabetic age- and sex-matched population
2
. 
Diabetes mellitus is a disease of antiquity. A polyuric state was described in the Ebers 
Egyptian papyrus and as long ago as 600 BC two main types were distinguished. The most 
famous description was made by Arateus the Cappadocian who talked of the melting down of 
flesh into urine and of the end being speedy. He was the first to use the term “diabetes”. Over 
the ensuing centuries sporadic descriptions were noted, with Maimonides in Egypt pointing 
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out its relative rarity. It was attributed to a salt-losing state although the sweetness of the 
urine had long been known
2
. 
The obvious breakthrough came in the 17th century with the demonstration of excess glucose 
in the urine and later also in blood. The presence of excess ketones was shown in the 19th 
century. Himsworth suggested division in insulin-resistant and insulin-sensitive type in 
1936
3
. Development of radioimmunoassay for insulin
4
 allowed the unequivocal 
demonstration of insulin deficiency or absence, in those with juvenile-onset (today type 1) 
diabetes while levels were apparently normal or elevated in those with maturity-onset (today 
type 2) diabetes. Autoimmune aetiology of type 1 emerged in focus in 1970s
5
. 
 
1.1.2 Diagnosis and classification  
Current diagnostic criteria for diabetes according to WHO
6
 and ADA
7
 are at least two of the 
following in a person with no current acute comorbidity (Table 1): 
 A random plasma glucose level ≥11.1 mmol/L (200mg/dL) in someone with 
symptoms of diabetes 
 A fasting plasma glucose level ≥7.0 mmol/L (126 mg/dL) 
 HbA1c>6.5% (48 mmol/mol) 
 A plasma glucose level ≥11.1 mmol/L (200mg/dL) 2 hours after a 75 g load of 
glucose given by mouth (the oral glucose tolerance test – OGTT) 
Use of a fasting plasma glucose (FPG) of 7mmol/L or higher to define diabetes (Table 1) 
originated from epidemiological studies in the 1990s, which showed that the risk of 
microvascular complications increases sharply at FPG threshold of 7 mmol/L. Lately, the 
notion of a clear glycaemic threshold separating people at high and low risk of diabetic 
microvascular complications has been brought to question. Part of the rationale for switching 
to glycosylated haemoglobin – HbA1c>6.5% (48 mmol/mol) as a diagnostic test is that 
moderate retinopathy is rare below this threshold. Also, greater standardisation of HbA1c 
assays has led to a recommendation that HbA1c>6.5% be used as a diagnostic cut-off for 
diabetes
8
. 
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Table 1  Classification of diabetes and glucose intolerance according to ADA fasting and WHO 2-h glucose criteria 
 Blood sample 
Plasma Capillary Whole 
Fasting blood glucose (mmol/L) 
Normal 
Impaired fasting glycaemia 
Diabetes 
 
2-h blood glucose 
Normal 
Impaired glucose tolerance 
Diabetes  
 
<6.1 <5.6 <5.6 
6.1-6.9 5.6-6.0 5.6-6.0 
≥7.0 ≥6.1 ≥6.1 
   
   
<7.8 <7.8 <6.7 
7.8-11.0 7.8-11.0 6.7-9.9 
≥11.1 ≥11.1 ≥10.0 
 
During the natural history of diabetes, the disease passes through intermediate categories of 
hyperglycaemia, so called – prediabetes. These stages are impaired glucose tolerance (IGT), 
defined as a plasma glucose of 7.8-11.0 mmol/L (140-200 mg/dL) 2 hours after glucose load 
in an OGTT and impaired fasting glycaemia (IFG), which is a different category based on 
fasting glucose levels of 6.1-6.9 mmol/L (110-125 mg/dL) according to WHO or 5.6-6.9 
mmol/L (100-125 mg/dL) according to ADA. 
Impaired glucose tolerance and impaired fasting glycaemia are intermediate metabolic stages 
between normal glucose homeostasis and the stage of diabetes. They do overlap, however, 
are not the same. They both are risk factors for developing future diabetes and cardiovascular 
disease. Various interventions to prevent overt diabetes in individuals with prediabetes have 
been studied
9
. Lifestyle modification (diet, exercise and weight loss) seems to be most 
efficient 
2, 3, 5
. 
The current classification of diabetes is made on the basis of supposed aetiology of the 
disease (Table 2). 
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Table 2 Classification of diabetes 
 Type 1 (β cell destruction, usually leading to absolute insulin deficiency) 
- Autoimmune 
- Idiopathic 
 Type 2 
Ranges from predominantly insulin resistant, with relative insulin deficiency, to a predominantly insulin-secretory defect, with or 
without insulin resistance 
 Other specific types 
- Genetic defects of β cell function 
- Genetic defects of insulin action 
- Diseases of exocrine pancreas 
- Endocrinopathies 
- Drug induced or chemical induced, e.g. steroids 
- Infections 
- Uncommon forms of immune-mediated diabetes 
- Other genetic syndromes sometimes associated with diabetes 
 Gestational diabetes 
 
There are four categories
8, 10
: 
 Type 1 diabetes (caused by pancreatic islet cell destruction) 
 Type 2 diabetes (caused by a combination of insulin resistance and β cell insulin 
secretory dysfunction) 
 Other specific types of diabetes 
 Gestational diabetes (defined as diabetes that occurs for the first time in 
pregnancy). 
Two major types are type 1 and type 2 diabetes. This classification has replaced the earlier, 
clinical classification into “insulin-dependent diabetes mellitus” (IDDM) and “non-insulin 
dependent diabetes mellitus” (NIDDM), which was based on the need for insulin treatment at 
diagnosis. IDDM is broadly equivalent to type 1 diabetes and NIDDM to type 2 diabetes. 
One of the most disadvantages of the old classification according to treatment was that 
subjects could change their type of diabetes. 
Type 1 diabetes mellitus (T1DM) is primarily caused by β-cell destruction although some 
insulin resistance is also present. After the initial stages, insulin is required for survival. In 
Europeans, more than 90% of type 1 diabetics show evidence of autoimmunity with anti-
glutamine acid decarboxylase (anti-GAD), anti-insulin and/or islet cell antibodies and still a 
growing number of other autoantibodies detectable, which is thought to be due to 
immunological destruction of pancreatic β cells11. In this way, the type 1 diabetes is 
subdivided into two main types: 1a or autoimmune (in which immune markers suggest 
autoimmune destruction of β cells), and 1b or idiopathic (where there is no evidence of 
autoimmunity)
2
. 
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By far the majority of people with diabetes worldwide have type 2 diabetes.  
Type 2 diabetes mellitus (T2DM) is a heterogeneous group of disorders characterized by 
variable degrees of insulin resistance, impaired insulin secretion, and increased glucose 
production. Distinct genetic and metabolic defects in insulin action and/or secretion give rise 
to the common phenotype of hyperglycaemia in type 2 diabetes mellitus. So it is 
characterized by insulin resistance with relative insulin deficiency (patients secrete insulin, 
but not enough to overcome the insulin resistance). Typically, they do not require insulin to 
survive but often will eventually need insulin to maintain reasonable glycaemia control, often 
after many years
1
.  
The exact molecular mechanisms underlying type 2 diabetes are not yet known. Major efforts 
have been made to discover the underlying genetic abnormalities but with only modest 
success: small scale studies of candidate genes and linkage studies identified few genes 
causing monogenic type 2 diabetes. In genome wide association studies (GWAS), more than 
50 loci are found to be associated with type 2 diabetes
12
. However, combined these loci 
account for not more than 10% of familiar clustering of type 2 diabetes in Europeans
13
. What 
is clear is that type 2 diabetes is closely associated with obesity and physical inactivity, and 
the westernization of lifestyles. The dramatic increase in type 2 diabetes over the past two 
decades has been closely paralleled by the rise in obesity worldwide. Both obesity, 
particularly visceral adiposity, and physical inactivity cause insulin resistance which will 
result in diabetes in those with only a small capacity to increase insulin secretion. The 
incidence of type 2 diabetes also increases with age, which may probably be related to 
decrease in exercise and muscle mass; however, the disease is now becoming a problem 
among younger ages and it is now not uncommon in adolescence and even in children. 
Sedentary lifestyle and obesity are the main contributory factors, although many have a 
positive family history of type 2 diabetes
2
. 
Type 2 diabetes occurs in families so that those with a first-degree relative with diabetes have 
an almost 50% lifetime risk
2
. There is also marked variation between different ethnic groups. 
Thus, those of Polynesian, Micronesian, South Asian, sub-Saharan African, Arabian and 
Native American origin are much more prone to develop diabetes than Europeans. Type 2 
diabetes is a diagnosis by exclusion and the prevalence may fall as causes are identified, but 
this is likely to be a slow process. 
The category of other specific types of diabetes (Table 3) is a large group of conditions, 
which includes genetic defects in insulin secretion (such as in maturity-onset diabetes of the 
6 
 
young (MODY) and insulinopathies), genetic defects in insulin action (e.g. syndromes of 
severe insulin resistance), pancreatitis and other exocrine disorders, hormone-secreting 
tumours such as acromegaly (growth hormone) and Cushing’s syndrome (cortisol). Some 
cases are caused by the administration of drugs such as glucocorticoids. Some genetic 
syndromes are sometimes associated with diabetes (e.g. Down’s syndrome, Klinefelter’s 
syndrome, and many more). 
7 
 
Table 3 Other specific types of diabetes 
Genetic defects of β-cell function 
 
 
 
 
 
Chromosome 20, HNF4 α (MODY 1) 
Chromosome 7, glucokinase (MODY 2) 
Chromosome 12, HNF1 α (MODY 3) 
Chromosome 13, IPF - 1 (MODY 4) 
Mitochondrial DNA 3243 mutation 
Others 
Genetic defects in insulin action 
 
 
 
 
Type A insulin resistance 
Leprechaunism 
Rabson – Mendenhall syndrome 
Lipoatrophic diabetes 
Others 
Disease of the endocrine pancreas 
 
Fibrocalculous pancreatopathy 
Pancreatitis (particularly chronic) 
Trauma/pancreatectomy 
Neoplasia 
Cystic fibrosis 
Haemachromatosis 
Others 
Endocrinopathies 
 
Cushing syndrome 
Acromegaly 
Pheochromocytoma 
Glucagonoma 
Somatostatinoma 
Others 
Drug- or chemical-induced 
 
Nicotinic acid 
Glucocorticoids 
Thyroxine/triiodothyronine 
α-adrenergic agonists 
Thiazides 
Pentamidine 
Vacor 
Others  
Infections 
 
Congenital rubella 
Cytomegalovirus 
Mumps 
Others 
Uncommon forms of immune-mediated disease 
 
Insulin autoimmune syndrome 
Anti-insulin receptor antibodies 
“Stiff man” syndrome 
Others 
Other genetic syndromes  
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Gestational diabetes mellitus (GDM) is hyperglycaemia first detected during pregnancy.  
There is a certain confusion in terms and criteria. Currently, WHO suggests
14
 partial adoption 
of International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria
15
. 
Thus, if a nonsymptomatic pregnant woman meets diagnostic criteria of diabetes during 
pregnancy it is diabetes in pregnancy (IADPSG uses term “overt diabetes”). Gestational 
diabetes is diagnosed at any time in pregnancy according to IADPSG criteria: 
Fasting plasma glucose: 5.1-6.9 mmol/l (92 -125 mg/dl)  
1-h post 75g oral glucose load: ≥10.0 mmol/l (180 mg/dl)  
2-h post 75g oral glucose load: 8.5 – 11.0 mmol/l (153-199 mg/dl)  
After previous acceptance of IADPSG approach to screening and diagnosis of gestational 
diabetes, current ADA guidelines suggest alternative (either/or) two-step approach with 50g 
glucose load in nonfasting individual with consequent measurement of BG after 60 minutes: 
if that is >7.8 mmol/L (140 mg/dL), a 100g OGTT should be performed and interpreted either 
to Carpenter-Coustan or National Diabetes Data Group 
7
. The two-step approach has not been 
widely used in Europe. 
Women with GDM have a high risk of developing later diabetes mellitus, usually type 2. 
Plasma glucose levels, both fasting and postprandial, are lower than normal in early 
pregnancy so that raised levels at this stage are almost certainly caused by previously 
undetected T2DM. Screening for GDM is generally undertaken in 24-28 week. 
There is significant morbidity associated with GDM including intrauterine faetal death, 
congenital malformations, neonatal hypoglycaemia, jaundice, prematurity and macrosomia. 
Risk factors for GDM include certain ethnic groups, those with previous GDM or 
abnormalities of glucose tolerance, age, obesity and previous large babies. 
 
The incidence of diabetes is rising owing to the sedentary lifestyle and an ever growing 
cluster of pre-diabetic syndromes including metabolic syndrome, obesity, and insulin 
resistance. The number of diabetic population is 382 million, and by 2035 is expected to 
increase to 592 million people throughout the world. The number of people with type 2 
diabetes is increasing in every country
16
. 
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1.1.3 Management of diabetes 
The overall goal of diabetes management is to achieve as near normal physiological or ideal 
values as possible, without detriment to quality of life and, for glucose control in particular, 
without causing significant hypoglycaemia
17
. 
Diabetes is a lifelong condition that is, for the majority, currently incurable. It is associated 
with premature mortality and morbidity from an increased prevalence of cardiovascular 
disease and microvascular complications affecting the kidney, nerve and eye
2
. High quality 
randomized trials have shown that improving glycaemic control is associated with a reduction 
in microvascular complications
18, 19, 20
 while a multifaceted approach to cardiovascular risk 
factors will reduce cardiovascular morbidity and mortality
21
. 
The person living with diabetes will spend the vast majority of their time managing their 
diabetes and only an estimated 1% of their time in contact with health care professionals. 
Therefore, the person with diabetes needs to be supported to take upon themselves much of 
the responsibility for the management of their diabetes. Given the central role of the person 
with diabetes and the relatively little contact with health care professionals, it is important 
that the purposes of the consultation or other contacts with the diabetes health care team are 
well defined and their aims are made clear so that the patient derives the maximum benefit 
from the time spent with their diabetes health care team, whether this is in a hospital or in a 
primary care setting. As well as the clinic visit, diabetes care may also be through phone or 
email contact or through educational sessions outside a traditional clinic setting. 
Much of the focus of care is directed towards minimizing the long-term complications 
through screening and working together with the person with diabetes to support improved 
glycaemic control and cardiovascular risk factor management. This provides a challenge for 
the diabetes team because people often have no symptoms at the time of care and yet are 
asked to make lifestyle changes and take medications that may place a considerable burden 
on that individual.  
 
Diabetes education 
Diabetes education continues to be a cornerstone of effective diabetes care and supports the 
philosophy of chronic care models. It is well established that the practice of diabetes self-
management education (DSME) is critical to the care and management of people with 
diabetes. Diabetes educators are being held more accountable for their role in diabetes 
management. Over time it has become apparent that education standards and a system or 
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framework describing self-care behaviour could have an important role in supporting people 
with diabetes to consider behaviour changes that might enhance their quality of life and 
support better management of their condition. The seven self-care behaviours are: healthy 
eating; being active; monitoring; taking medicine; problem-solving; reducing risks; and 
healthy coping
2
. 
DSME is a comprehensive patient education structure to help achieve the necessary 
metabolic outcomes and improve the lives of those living with diabetes. Metabolic 
improvements such as glucose, lipids and blood pressure (BP) in type 2 diabetes care are best 
achieved with a healthy lifestyle and appropriate use of pharmacologic interventions. 
 
Lifestyle change: Diet 
Nutritional management in diabetes aims to assist in optimizing metabolic control and 
reducing risk factors for chronic complications. This includes the achievement of blood 
glucose and glycosylated haemoglobin (HbA1c) levels as close to normal as is safely possible 
and serum lipid concentrations as well as blood pressure values that may be expected to 
decrease the risk for macrovascular disease. Individual therapeutic needs and the quality of 
life of the person with diabetes have to be considered when nutritional objectives are 
defined
2
. 
 
Lifestyle change: Exercise 
Regular exercise increases insulin sensitivity in individuals with and without diabetes. In 
individuals without diabetes, plasma insulin levels decrease during low to moderate intensity 
exercise to compensate for increases in insulin sensitivity. Glucose production and glucose 
disposal increase in parallel in order to maintain blood glucose homeostasis
2
. 
Structured supervised diet and exercise interventions can reduce by about 60% the risk of 
developing type 2 diabetes mellitus in individuals with impaired glucose tolerance
2, 22
. In type 
2 diabetes, regular exercise improves glycaemic control significantly 
2, 3
. 
 
Monitoring diabetes 
Glycaemic control should be monitored regularly for all patients with diabetes. The optimal 
method of determining risk of long-term complications is through HbA1c measurement, 
although if this is not available, then examination of a series of blood glucose measurements, 
including fasting tests, may provide some guidance.  
11 
 
Drug therapy 
According to the results of key researches on association of glycaemic control and the 
development of diabetic complications, the target for good glucose regulation is 
normoglycaemia. However, it was recently shown that aggressive regulation of glucose level 
in patients with associated diseases (especially cardiovascular) in critically ill patients is not 
justified, and may even be harmful. It is therefore recommended individually to specify the 
target control in patients with respect to age, duration of disease, comorbidities (especially 
cardiovascular) and life expectancy. The general rule is: the younger the patient, the less 
suffering from diabetes, with fewer complications and comorbidities, the firmer the glucose 
regulation level. ADA breaks down the target glycaemia presenting recommendations to 
lower levels for a target HbA1c <7% in most patients, for those younger without 
complications <6.5%, and for patients with severe accompanying diseases and shortened 
expected duration of life <8%. 
 
Medications to control blood glucose level  
Medications to control blood glucose are traditionally divided into oral anti-diabetics (oral 
hypoglycaemic agents) and insulin. From the advent of non-insulin injectable drugs (GLP1 
mimetics, pramlitid) this classification is not suitable, and it is better to talk about non-insulin 
medication and insulin. 
 Insulin  
Insulin was first applied in 1922. The introduction of the highly purified insulin preparations 
from 1970s significantly reduced the number of adverse reactions associated with impurities 
in preparations. Insulin in the 1980s was the first peptide for the treatment, obtained by 
recombinant DNA techniques ("human" insulin). There are no clinically significant 
differences between highly purified animal and human insulin. 
Insulin preparations differ in the length of action. The effect of conventional (animal and 
human) short-acting insulin starts 30-60 minutes after subcutaneous injection and lasts 6-8 
hours. Physiological increase of insulinaemia at a meal is shorter. Short-acting analogues 
(lispro, aspart and glulizin) have been developed with the aim of better imitation of insulin 
secretion that occurs during a meal. Insulin and short-acting analogues can be administered 
intravenously, and for continuous subcutaneous infusion pump. Prolonged action is achieved 
by crystallization of insulin in the presence of zinc ions (Lente insulin) or by binding to the 
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neutral protamine suspension (NPH = Neutral Protamine Hagedorn), and pharmacodynamic 
characteristics of these compositions are the same. NPH insulin showed marked variability 
that is associated with unpredictable episodes of hypoglycaemia. Analogues of prolonged 
action, glargine and detemir, were developed with the idea of less variability and predictable   
basal insulinaemia. 
Biphasic, pre-mixed insulins are a mixture of rapid-acting and long-acting insulin in different 
proportions (typically 30% faster and 70% of extended components). Also, pre-mixed 
analogue insulins are available. 
Insulin in type 1 diabetes  
Multiple-dose insulin therapy, the so called basal-bolus therapy, is an appropriate initial 
approach to reproducing the physiologic insulin profile in patients with absolute insulin 
deficiency such as those with type 1 diabetes. This consists of a long-acting insulin 
preparation administered once or twice a day to meet the basal insulin requirement, with the 
injection of a short-acting insulin preparation with each meal.  
The modern approach involves calculating the needs of bolus insulin to the amount of 
carbohydrates in a meal that gives greater freedom in choosing food. The calculation should 
include the amount needed for the correction of glycaemia, if it is too high before meals. 
Substitution therapy with insulin is the most challenging endocrine substitution, which 
necessarily means a permanent activity of the patient and it is necessary to educate and train 
for such treatment. 
Insulin in type 2 diabetes mellitus  
Insulin may be required from time to time and occasionally in the treatment of type 2 
diabetes. Most often it is required to be used in intercurrent disease, and sometimes at the 
beginning of the disease that manifests ketoacidosis (so-called ,,ketosis prone to,, type 2  
diabetes) and that needs to be corrected with insulin. 
A number of different insulin injection regimens are available for patients with type 2 
diabetes who may already be treated with non-insulin-based therapies. These include a once 
daily injection of a long-acting insulin, a once daily injection of a long-acting insulin with an 
injection of a short-acting insulin with the main meal, twice a day injections of insulin 
mixtures, and multiple dose injections. Regardless of the choice of initial treatment schemes 
(boluses, basal or pre-mixed) after about a year the majority of patients will no longer be able 
to maintain target glycaemia and it will be necessary to intensify treatment. 
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Side effects of insulin  
The most serious complication of insulin injection for most people is hypoglycaemia. 
Hypoglycaemia is almost an inevitable side effect of insulin therapy. Patients should be 
taught about the recognition of hypoglycaemia, the reasons for its creation (the balance of 
food, exercise and insulin) and how to act in case of its occurrence (extra meal, glucose 
sweets). The family should be taught about the application of glucagon. With respect to 
insulin treatment, the fear of hypoglycaemia may be a major barrier to insulin initiation and 
achievement of tight glycaemic control. 
Insulin can also lead to excessive weight gain. This remains a major concern for many 
patients, particularly for the already overweight patient with T2DM who can no longer be 
controlled on oral hypoglycaemic agents. Weight gain can be reduced by concomitant advice 
from the dietitian and an insulin regimen tailored to the individual needs of the patient, that 
wherever possible provides most insulin when needed (i.e. at meal times). Overaggressive 
insulin titration regimens leading to low blood glucose and stimulation in appetite can lead to 
excessive weight gain. 
Allergy to insulin is not common, and among them local skin reactions are more frequent, 
while systemic are rare. These reactions usually occur in those with information on the 
history of allergy.  
Lipohypertrophy at the site of injections is due to frequent injections in the same place. 
Lipoatrophy is extremely rare with purified insulin preparations. According to 
epidemiological data, there is a somewhat higher incidence of malignant diseases in people 
with diabetes. It seems that the said has further increased with insulin treatment, probably 
because of the possibility that insulin stimulates the growth of existing tumours.   
 Non-insulin medications 
Metformin  
The biguanide metformin is often selected as initial oral antidiabetic drug therapy. It counters 
insulin resistance and lowers blood glucose through several insulin-dependent and 
independent mechanisms, notably reducing hepatic glucose production and also increasing 
glucose uptake by skeletal muscle. It does not stimulate insulin secretion, carries a low risk of 
frank hypoglycaemia, and does not cause weight gain. Metformin also exerts several 
potentially beneficial effects on cardiovascular risk factors independently of glycaemic 
control, with evidence of improved long-term cardiovascular outcomes. Metformin may be 
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conveniently combined with other classes of antidiabetic drugs. Gastrointestinal side effects 
including diarrhoea limit the use of metformin. These side effects are usually transient and 
rarely occur with the gradual introduction of the drug and the application after meals. The 
maximum daily dose is of 3 g, and usually is 2 g separated twice daily. The rare but serious 
adverse effect of lactic acidosis excludes the use of the drug in patients with significant renal 
insufficiency, significant liver disease or any condition predisposing to hypoxia or 
hypoperfusion including cardiac or respiratory failure. 
Few cohort studies showed lower mortality rates to treatment with metformin compared to 
sulphonylurea derivates. The observational studies found less cardiovascular events with 
metformin compared to other oral hypoglycaemic agents, and there are indications of 
antitumour activity and modulation of incretin effect. 
Sulphonylureas 
These are the oldest drugs to control hyperglycaemia. Sulphonylureas (e.g. gliclazide, 
glimepiride, glibenclamide/glyburide, glipizide) act on the pancreatic β cells to stimulate 
insulin secretion. 
They bind to the transmembranal complex of sulphonylurea receptors SUR1 with ATP-
sensitive Kir6.2 potassium efflux channels. This closes the channels, depolarizes the 
membrane, opens voltage-dependent calcium channels, and raises intracellular free calcium 
concentrations. 
This in turn activates proteins regulating insulin secretion. The efficacy of sulphonylureas 
depends on adequate remaining function of the β cells. Sulphonylureas stimulate insulin 
secretion independent of glucose, the main side effects are hypoglycaemia and weight gain. 
Hypoglycaemia is the most serious adverse effect and occurs mainly due to poorly supervised 
treatment of elderly people, especially those with renal failure, particularly with longer acting 
sulphonylureas. Caution with hepatic and/or renal insufficiency is warranted in accordance 
with the metabolism and elimination of individual preparations, and interactions with other 
protein-bound drugs can occur. 
Meglitinides 
Meglitinides (repaglinide and nateglinide), also known as prandial insulin releasers, are rapid 
and short-acting insulin secretagogues taken before meals to boost insulin levels during 
digestion, thereby reducing prandial hyperglycaemia and decreasing the risk of interprandial 
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hypoglycaemia. They act in a similar manner to sulphonylureas by binding to a “benzamido” 
site on the SUR1 – Kir6.2 complex. They are conveniently used in combination with an agent 
that reduces insulin resistance. 
Intestinal glucosidase inhibitors 
Intestinal glucosidase inhibitors (acarbose and miglitol) competitively bind to glucosidase, 
thereby slowing down the absorption of carbohydrates. Acarbose is minimally absorbed from 
the gastrointestinal tract and therefore has no systemic side effects. Common side effects 
include bloating and flatulence due to fermentation in the gut with too many carbohydrates 
from the food. It should not be used in patients with severe renal insufficiency (creatinine 
clearance less than 25 mL / min). 
Thiazolidinediones (glitazones) 
Thiazolidinediones (pioglitazone and rosiglitazone) produce a slow-onset glucose-lowering 
effect, attributed mainly to increased insulin sensitivity. They alter the expression of certain 
insulin-sensitive genes by stimulating the peroxisome proliferator-activated receptor γ, 
increasing adipogenesis, and rebalancing the glucose-fatty acid (Randle) cycle. 
Thiazolidinediones can be used as monotherapy or in combination with other classes of 
antidiabetic agents. They have low risk of hypoglycaemia but often cause weight gain. The 
potential for fluid retention and an attendant risk of congestive heart failure should be borne 
in mind, especially in combination with insulin. 
Thiazolidinediones are not recommended for individuals at high risk of cardiac disease or 
women with reduced bone density. 
Contraindication of their use is heart failure due to fluid accumulation indicated preferences. 
They work on many cardiovascular risk factors, but the long-term favourable cardiovascular 
effects are not unambiguously proven. The use of thiazolidinediones (glitazones) is 
significantly limited because of the side effects, and because of causing fatal liver failure 
troglitazone (first drug of this group) was withdrawn from the market. Rosiglitazone was, due 
to cardiovascular side effects (myocardial infarction), withdrawn from the market in Europe 
and the US. Also, higher incidence of bone fractures was observed with the use of 
rosiglitazone and pioglitazone. Pioglitazone was, due to indications of higher incidence of 
bladder cancer, in 2011withdrawn from the markets of Germany and France, and other 
European countries and the United States. They listed bladder cancer (active or history) and 
haematuria of unknown cause as contraindications for use. 
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Sodium-glucose cotransporter inhibitors (gliflozines) 
By inhibition of reabsorption of glucose (and sodium) in renal tubuli these drugs lower BG 
and are helpful in weight management. Most common side effects are genitourinary 
infections. 
Drugs based on incretin effect 
The incretins are a group of gastrointestinal hormones that enhance glucose-stimulated 
insulin secretion and have an important role in the regulation of postprandial glucose levels. 
Glucagon-like peptide (glucagon-like peptide-1, GLP-1) is an incretin secreted by the L cells 
of the small intestine induced by the meal. The physiologic actions of GLP-1 include 
potentiation of meal-induced insulin secretion, inhibition of glucagon secretion, delay in 
gastric emptying and suppression of food intake and appetite. GLP-1 coordinates the 
secretion of insulin and glucagon depending on glycaemia and thus helps glucose level 
regulation without the risk of hypoglycaemia. In experimental models it promotes the growth 
of β-cells and prevents cell apoptosis. Degradation and inactivation of GLP-1 is faster under 
the effect of enzyme dipeptidyl-peptidase-4 (DPP-4) and for therapeutic purposes can be used 
only continuous infusion. The research is turned in the direction of the synthesis of drugs that 
would act as a GLP-1, but would be resistant to the enzyme DPP-4 (mimetics), and towards 
another group of drugs that inhibit this enzyme (DPP-4 inhibitors or blockers). Mimetics 
therapy achieves ten times higher concentrations compared to DPP-4 inhibitor achieved level 
and that could be a possible reason for the differences in effects, since mimetics have a 
pronounced drop in body weight, which is not the case with the DPP-4 inhibitors. 
Incretin mimetics (exenatide, liraglutide) are applied as subcutaneous injections, and are 
suitable for the treatment of patients with type 2 diabetes with a higher degree of obesity. The 
most common side effect is nausea and vomiting. In some studies there are indications of a 
higher risk for occurrence of pancreatitis, but this has not been confirmed by a retrospective 
cohort study and systematic monitoring of side effects. In rodents, a correlation between C-
cell hyperplasia and medullary thyroid cancer has been observed, but this is probably due to 
the effect of a specific type because rodents have distinct expression of the receptor for GLP-
1 in C cells of the thyroid. Closely monitoring of the incidence of medullary carcinoma in 
people with the use of GLP-1 mimetics has not so far given indication to that effect. 
DPP-4 inhibitors by preventing the degradation of GLP-1 prolong the effect of the incretin, 
and increase its circulating level. These are oral medications known as gliptins (sitagliptin, 
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saxagliptin, vildagliptin, linagliptin). They are structurally different, and therefore have a 
different and specific blockade of DPP-4 isoenzymes. Based on clinical experience, no 
significant differences have been registered in safety between clinical applications of so far 
used DPP-4 inhibitors, and neither severe side effects. Indications of frequent incidence of 
pancreatitis have not been confirmed. 
Pramlintide, is an amylin analogue registered for blood glucose control in the US, not in 
Europe. Amylin is a naturally occurring peptide that is co-secreted with insulin from the β 
cells of the pancreatic islets. Physiologic actions of amylin include delayed gastric emptying, 
suppression of postprandial glucagon secretion, and increased satiety. Beneficial effects of 
parenteral administration of pramlintide, a synthetic amylin mimetic approved for use in 
insulin-treated subjects with either type 1 or type 2 diabetes, include improved glycaemic 
control and mild weight loss. It is used for type 1 and type 2 diabetes in combination with the 
standard insulin therapy. The overall effect is better prandial blood glucose control and lower 
insulin requirements. The drug is administered by subcutaneous injection, and side effects are 
hypoglycaemia, nausea, abdominal pain, and headache. 
Bromergocriptin and Colesevelam are registered for blood glucose lowering in the US, not in 
Europe. 
 
Management of type 2 diabetes – Guidelines for pharmacotherapy 
Several approaches to the best management of T2DM have been proposed. All algorithms 
begin with therapeutic lifestyle change (diet and exercise) and are generally focused primarily 
upon controlling hyperglycaemia. 
The American Diabetes Association (ADA) and the German Diabetes Society, whose 
guidelines with adjustments have been adopted also by the Croatian Society for Diabetes and 
Metabolic Disorders, recommend to include immediately metformin at diagnosis, of course, 
if there are no contraindications (Figure 1).  
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Diagnosis of type 2 diabetes 
Education, nutrition therapy, exercise therapy, metformin 
If metformin contraindicated/not tolerated and HbA1c > 6.5%* after 3–6 months 
of non-pharmacological therapy: 
α-glucosidase inhibitors, glitazones, repaglinide, SU (alphabetical listing)
HbA1C≥6,5% 
after 3-6 months of monotherapy
HbA1C ≥ 6,5%
after 3-6 months 
of combination 
therapy 
HbA1C ≥ 6,5%
after 3-6 months of
OH + insulin therapy
Intensification of insulin therapy 
•MDI (basal/bolus): basal insulin + prandial insulin one to three times a day 
•Premixed insulin bid, if MDI not possible/not indicated 
•Combination with metformin, if no contraindication/intolerance
•Further option: combination with pioglitazone, if no contraind./intol. 
•Further option: CSII, if therapeutic goal is not achieved with MDI
Metformin
+
Metformin
+
acarbose
SU
Glinid
(SUA)
DPP-4 
Inhibitor
GLP-1
analog
glitazone
premixed insulin
HbA1C≤7,5% HbA1C>7,5%
 
Figure 1 Guidelines for treatment of type 2 diabetes from American Diabetes Association (ADA) and the German Diabetes 
Society, also adopted and adjusted by the Croatian Society for Diabetes and Metabolic Disorders.  
 
The ADA and the German Diabetes Society recommend to begin immediately the treatment 
with metformin. When metformin alone is insufficient, the addition of a second drug is 
recommended. Guidelines of International Diabetes Federation (IDF) distinguish between the 
conventional and the alternative approach that does not include the initial phase of treatment 
by pharmacotherapy. The first line of treatment is only basic treatment, which involves a 
lifestyle change (Figure 2). 
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Life Style measures
Metformin
Sulfonylurea
Basal + 
meal-time
insulin
Basal insulin, or
Pre-mix insulin
(later basal + meal –
time)
Basal insulin
or
Pre-mix insulin
α-Glucosidase
inhibitor or
DPP-4 inhibitor or
Thiazolidinedione
Metformin
(if not first line)
α-Glucosidase
inhibitor or
DPP-4 inhibitor or
Thiazolidinedione
GLP-1 agonist
Sulfonylurea
or
α-Glucosidase
inhibitor
Then, at each step, if not to target (generally HbA1C<7.0 %)
Consider first line
Consider second line
Consider third line
Consider fourth line
or
oror
=usual approach
=alternative approach
 
Figure 2  Guidelines for treatment of type 2 diabetes from International Diabetes Federation (IDF). 
 
All societies agree that we should have a proactive attitude, if it is sufficient, to intensify the 
therapy by combining drugs. If there are contraindications to metformin use, it can be started 
with the drug from another group as the first line drug. We should interpret with caution 
reports on the average decline of HbA1c with an individual therapy, which is regularly 
increasing regardless of the treatment as much as starting HbA1c is greater. Comparison of 
the effectiveness of drugs regularly conducted by the Agency for Healthcare Research and 
Quality in Health Care USA shows that all non-insulin drugs have similar effects on HbA1c: 
about 1%. With sulphonylureas hypoglycaemia is four times more frequent compared with 
metformin, up to 5 times more in combination. Mean body weight difference is -2.5 kg with 
metformin compared to sulphonylurea and pioglitazone.  
20 
 
The aim of ideal glucose regulation is HbA1c <6.5%. It is important to emphasize individual 
approach with regard to the characteristics of the patient, especially comorbidities, 
complications of diabetes, and age. For some patients a less strict target should be determined 
(HbA1c <7% or <7.5%). If with metformin alone (or other treatment in case of 
contraindications) after 3-6 months the target level is not achieved, recommendation is to add 
a drug from other groups, as the mechanisms of action of various drugs can be combined with 
each other. After the next 3-6 months estimated effect, if the goal is not achieved, adding an  
additional medication or insulin is recommended. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
1.2 Osteocalcin 
Until recently, endocrinologists have looked upon bone as a target for hormones such as sex 
steroids, parathyroid hormone (PTH), and calcitonin. The skeleton was seen as a mere 
protective casing for cells and their cytokine products, and perhaps the bone was only thought 
of as a useful support system. Discoveries in the past decades revealed that bone mass is also 
regulated by the fat via leptin which acts upon brain and downstream through hypothalamic 
relay and sympathetic nervous system
23, 24
. These findings suggested, from endocrine point of 
view, that a feedback mechanism should exist. Indeed, recent studies and pharmacological 
experiments in mice suggest an entirely new role for bone, by producing osteocalcin that acts 
as a hormone affecting insulin production and sensitivity, glucose utilization and energy 
expenditure
25
. These findings have been reviewed recently
26, 27, 28
.  
Osteocalcin (OC) (also called bone ɣ-carboxyglutamic acid protein, or BGP) is a bone-
specific protein secreted by the osteoblasts consisting of 46–50 residues (Figure 1)29 that 
undergoes post-translational modification by vitamin- K-dependent ɣ-carboxylation of three 
glutamic acid residues
30
. Undercarboxylated osteocalcin (ucOC) has fewer than three 
carboxylated residues, and has a lower affinity for bone. The fully carboxylated and 
undercarboxylated forms of osteocalcin are both found in serum. Osteocalcin is expressed by 
mature osteoblasts, binds strongly to hydroxyapatite, stored in bone matrix and released into 
the circulation, and is a useful marker of bone formation
27
. 
 
 
 
Figure 3 Diagram of the osteocalcin structure. Gla residues are present at positions 17, 21 and 24 and a disulphide bridge is 
present between residues 23 and 29. 
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Knock-out mice (null) for osteocalcin (OC
_/_ 
mice) show no remarkable bone phenotype but 
appear mildly hyperglycaemic and have slightly increased visceral fat
31
. On the other side, 
deletion of the Esp gene (Esp 
_/_ 
mice), a gene encoding a receptor-like protein: 
osteotesticular protein tyrosine phosphatase (OST-PTP), results in a phenotype opposite that 
of the OC
_/_ 
mice: increased pancreatic islet size, ß-cell number and circulating insulin levels; 
increased insulin sensitivity despite hypoglycaemia, decreased visceral fat mass; increased 
expression of insulin target genes in the liver and muscle, energy expenditure increased, 
while food intake is not affected
24
. 
In ex vivo experiments, osteocalcin stimulates cyclinD1 and insulin expression in β cells and 
adiponectin, an adipokine whose overexpression enhances insulin sensitivity
32
. Insulin 
production and insulin sensitivity is shown to be enhanced by either addition of osteocalcin or 
overproduction of osteocalcin by osteoblasts. In vivo treatment of normal mice with non-ɣ-
carboxylated osteocalcin generated by bacterial expression found increased pancreatic ß-cell 
numbers, insulin secretion, energy expenditure and insulin sensitivity so it has the opposite 
effect on metabolism as that in the OC
_/_ 
mice
 33
. So Esp 
_/_
 mice are also protected from 
diabetes, similar to treated mice with non-ɣ-carboxylated osteocalcin while alternately, bone-
specific overexpression of OST-PTP resulted in a phenotype identical to OC
_/_ 
mice. 
Therefore, the hypothesis was made that OST-PTP was responsible for inactivating OC 
through ɣ-carboxylation25.  
In summary, osteocalcin may act as a metabolic hormone whose regulation is not yet 
elucidated and receptor-like protein osteotesticular protein tyrosine phosphatase (OST-PTP) 
could be involved in still unclear signalling pathways. 
The information about the role of circulating osteocalcin and particularly its 
undercarboxylated fraction on energy expenditure and the regulation of insulin secretion was 
derived from studies on mice models in which osteocalcin production was inactivated or 
increased. 
An equivalent to mice OST-PTP in humans has not been identified. However, blood 
osteocalcin levels were shown to be significantly lower in diabetics than in non-diabetic 
controls, and the levels were inversely related to fat mass and blood glucose
34, 35
. In 
postmenopausal women, osteocalcin levels were significantly lower in type 2 diabetic 
subjects than in controls
36
. In a study on effects of hypocaloric diet and exercise, osteocalcin 
plasma levels were associated positively with insulin sensitivity and negatively with fasting 
plasma triglycerides
37
. Serum osteocalcin level is associated with glucose metabolism and 
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atherosclerosis parameters in patients with type 2 diabetes
38, 39
. In gestational diabetes, higher 
level of osteocalcin in comparison with pregnancies with normal glucose tolerance is 
observed
40
. In poorly controlled diabetics, after only a month of treatment and glycaemic 
control, increase of osteocalcin level was seen while serum adiponectin was not significantly 
different before and after glycaemic control, but baseline level of adiponectin seems to 
predict the beneficial bone reaction
41
. Osteocalcin level seems to increase after improved 
glycaemic control in type 2 diabetes
,42, 43 
. 
Most of these earlier studies
41, 42
 were focused on the effect of diabetes on bone remodelling 
and level of osteocalcin on humans. The role of osteocalcin in regulation of glucose 
metabolism remains to be elucidated.  
Most clinical studies investigating possible metabolic effects (or associations) with 
osteocalcin levels did not distinguish total (TOC) and undercarboxylated osteocalcin (ucOC). 
Experimental data
25, 32
 suggest that undercarboxylated osteocalcin (ucOC) is involved in 
metabolism. Recent data from healthy children suggest the same relationship in humans
44
.  
Improved glycaemic control appears to increase TOC but does not necessarily have the same 
effect on ucOC. Additional studies with ucOC as an outcome are needed to clarify the effects 
of improved glycaemic control on this marker. 
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2 HYPOTHESIS  
 
Undercarboxylated osteocalcin level is associated with changes in the level of glucose control 
assessed by HbA1c; i.e. undercarboxylated osteocalcin (ucOC) is involved in glucose 
metabolism not related to bone turnover. Osteocalcin levels in diabetics and its relation to 
blood glucose control might reflect this association. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
3 AIMS OF THE STUDY 
3.1 Main Aims of the study  
1.  Association of serum ucOC level and HbA1c as a marker of glucose regulation in 
type 2 diabetes. 
2.  Changes in serum ucOC with short term (three months) improvement of blood 
glucose control in terms of HbA1c in persons with type 2 diabetes. 
 
3.2 Specific Aims 
1. To assess the relationship of serum TOC and ucOC level with insulin sensitivity 
assessed by HOMA indexes. 
2. To assess the relationship of serum TOC and ucOC level with BMI. 
3. To show that changes in ucOC with glucose regulation (if present) are independent 
of bone turnover. 
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4 MATERIALS AND METHODS 
 
4.1 Subjects 
A total of 57 consecutive type 2 diabetic patients (WHO criteria), male and female, aged 19-
79, whose diabetes was treated by diet only, with HbA1c of 7.5 % or over, participated in this 
study. 
Exclusion criteria included: malignant diseases, kidney or liver diseases, bone metabolism 
disease, glucocorticoid treatment, hormonal contraception, hormonal replacement treatment, 
and androgen treatment.  
The recruited patients were from an outpatient department or hospitalized in the Clinic of 
Internal Medicine, Zagreb Clinical Hospital Centre. 
 
4.2 Methods 
Clinical data, patient history 
All patients underwent physical examination, including blood pressure measurement. 
Measurements of height and weight were taken. Body mass index (BMI) was calculated as 
weight (kg) per height (m
2
).  
Assessment of insulin resistance in the basal state was estimated by the homeostasis model 
assessment (HOMA) for insulin resistance (HOMA-IR), for estimate steady state of beta cell 
function (HOMA B%) and insulin sensitivity (HOMA S)%
45
, calculated from fasting blood 
glucose and fasting insulin by downloaded calculator
46
.  
 
Analytical procedures – Biochemical measurements 
Blood was collected after an overnight fasting, at baseline and after three months. Samples 
were separated and stored frozen until assay. Measurements of the following levels were 
taken: TOC, ucOC, fasting blood glucose (FBG), fasting insulin, HbA1c and bone turnover 
marker (crosslaps telopeptide).The used methods for measurement of  parameters are 
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standard recommended biochemical methods („ligand“) automated or semi-automated 
performed according to the manufacturer’s instructions. 
Insulin, HbA1c, osteocalcin, beta-crosslaps were measured on Roche instruments by Roche 
reagents (Roche Diagnostics, Mannheim, Germany). Undercarboxylated osteocalcin, Takara 
Bio Inc., Japan.     
 
4.3 Statistical analysis 
A descriptive analysis is presented in tables and figures.  
Numeric variables were tested for distribution normality using the Shapiro-Wilk’s test. All 
variables were distributed significantly different than normal distribution. Therefore, non-
parametric tests were used for group comparison (Wilcoxon test for dependent samples) and 
correlations (Spearman rho test). 
The level of statistical significance is chosen to be 0.05.  
The SPSS ver. 17.01 was used to perform statistical analysis (SPSS ID: 729038). 
Calculated sample size for assessment of association correlation of serum osteocalcin and 
HbA1c level (from the published data, coefficient is -0.3) for power of 80% was 25 per 
group. From published data, standard deviation of HbA1c in population is 2.5; thus for 1% 
difference in HbA1c sample size was 50 assuming that at least half of them would reach a 1% 
decrease in HbA1c.  
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4.4 Ethics 
This study was conducted according to all currently valid and applied guidelines whose 
purpose is to assure proper conduction and protection of persons included in this research as 
examinees, including the Basics of Good Clinical Practice and Helsinki Declaration, Health 
Protection Law of the Republic of Croatia (NN 121/03), and Patient’s Rights Law of the 
Republic of Croatia (NN 169/04). 
Identity of healthy examinees and patients remained confidential and protected.   
 
Consent form and subject information 
Prior to the beginning of the trial, the investigator presented oral and written information 
about the study. The investigator had to be ensured that subjects were fully informed about 
the aim of the study, procedures, potential risks, discomforts, and expected benefits which 
could come out from these investigations. Also, subjects were informed and agreed that the 
Health Authority personnel would require the access to data. It was emphasized that 
participation would be voluntary and that subjects would have the right to withdraw from the 
trial at any time without prejudice. A freely given, written Informed Consent was obtained 
from all subjects prior to their admission to the procedures in accordance with the study 
protocol. 
 
Ethics committee 
Prior to the start of the trial, all three documents – research design of the thesis project 
proposal, informed consent, and agreement letter for participation of subjects, – were 
submitted to the Ethics Committee of Zagreb Clinical Hospital Centre and of the School of 
Medicine, University of Zagreb. A written approval for these documents was obtained. 
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5 RESULTS 
A total of 57 patients participated in the study: 21 (36.8%) females, 36 (63.2%) had 
hypertension. A descriptive analysis is presented in tables and figures. Basal characteristics of 
patients are shown in Tables 4-5 and Figures 4-7. 
 
Table 4 Basal patient characteristics and parameters at Visit 1  
  
Mean Median 
Std. 
Deviation Range Minimum Maximum   
AGE [years] 54.4 57.0 10.4 50.0 30.0 80.0 
HEIGHT [m] 1.7 1.7 0.1 0.4 1.5 1.9 
WEIGHT_1 [Kg] 88.8 88.0 15.3 69.0 66.0 135.0 
body mass index (BMI)_1 [Kg/m2] 29.9 29.2 4.0 20.4 23.2 43.6 
glycosylated haemoglobin (HbA1c)_1 [%] 8.5 8.0 1.6 5.7 6.3 12.0 
fasting blood glucose (FBG)_1 [mmol/L] 9.5 9.0 1.9 7.9 7.1 15.0 
insulin_1 [uU/L] 24.9 18.0 26.9 179.3 3.7 182.9 
HOMA B%_1 19.8 15.0 17.5 101.2 3.9 105.1 
HOMA S%_1 259.8 218.9 202.0 1036.6 23.0 1059.6 
HOMA-IR_1 0.6 0.5 0.6 4.3 0.1 4.3 
total osteocalcin (TOC)_1[ug/L] 12.2 11.8 4.6 28.2 6.2 34.4 
undercarboxylated osteocalcin(ucOC)_1 [ng/mL] 2.3 2.0 1.9 7.9 0.1 8.0 
crosslaps_1 [ug/L] 0.2 0.2 0.1 0.5 0.1 0.6 
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Figures 4-7 show distribution histograms and normal curve for age (years), BMI (Kg/m
2
), 
HbA1c (%) and undercarboxylated osteocalcin (ucOC, ng/mL) at Visit 1. 
 
Figure 4  Age of participants: frequency histograms and normal curve 
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Figure 5  Body mass index (BMI) of participants at Visit 1: frequency histograms and normal curve 
 
Figure 6  Glycated haemoglobin (HbA1c) of participants at Visit 1: frequency histograms and normal curve 
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Figure 7  Undercarboxylated osteocalcin (ucOC) of participants at Visit 1: frequency histograms and normal curve 
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A total of 47 patients completed the study. Parameters at Visit 2 are shown in Table 5. 
 
Table 5  Patient parameters at Visit 2 
  
Mean Median Std. Deviation Range Minimum Maximum   
HbA1c_2 [%] 6.9 6.5 1.2 4.9 5.0 9.9 
WEIGHT_2 [Kg] 86.8 85.0 14.3 66.0 61.0 127.0 
BMI_2 [Kg/m2] 29.2 28.7 3.5 18.4 22.6 41.0 
FBG_2 [mmol/L] 7.2 7.0 0.9 4.0 6.0 10.0 
insulin_2[uU/L] 22.6 21.5 17.7 69.0 3.8 72.9 
HOMA B% _2 28.0 23.8 16.1 68.1 5.2 73.3 
HOMA S%_2 312.1 188.7 256.4 1029.6 56.7 1086.3 
HOMA-IR_2 0.5 0.5 0.4 1.7 0.1 1.8 
TOC_2 [ug/L] 12.6 12.9 4.3 18.3 7.0 25.3 
ucOC_2 [ng/mL] 1.5 1.4 1.0 3.3 0.2 3.5 
crosslaps_2 [ug/L] 0.2 0.2 0.1 0.4 0.1 0.5 
  
 
Numeric variables were tested for distribution normality using the Shapiro-Wilk’s test. All 
variables were distributed significantly different than normal distribution (as presented in Fig 
4-7). Therefore, non-parametric tests were used for group comparison (Wilcoxon signed rank 
test) and correlations (Spearman rho test). The level of statistical significance was chosen to 
be 0.05. 
 
Correlation of total and undercarboxylated osteocalcin levels with BMI, insulin, HOMA 
indexes were tested. The only significant correlation was a negative one between BMI and 
ucOC level at Visit 1 (Spearman's rho -0.295; p=0.026) (Figure 8). 
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Figure 8 Scatter plot for undercarboxylated OC level and BMI at Visit 1 
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Average weight, BMI, HbA1c, FBG, insulin, HOMA B%, HOMA S%, HOMA-IR, total and 
undercarboxylated osteocalcin (ucOC) and crosslaps at Visit 1 and 2 are presented by box-
and-whiskers plot ((median, quartiles, range, outliers and extremes) shown in Fig 9-19. 
 
Figure 9  Body weight (kg) at Visit 1 and 2 
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Figure 10 Body mass index (BMI) at Visit 1 and 2 
 
Figure 11 Glycated haemoglobin (HbA1c) at Visit 1 and 2 
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Figure 12 Fasting blood gucose (FBG) at visit 1 and 2 
 
Figure 13  Insulin (ins) at Visit 1 and 2 
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Figure 14   HOMA B% at Visit 1 and 2 
 
Figure 15    HOMA S% at Visit 1 and 2 
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Figure 16    HOMA-IR at Visit 1 and 2 
 
Figure 17    Total osteocalcin (TOC) at Visit 1 and 2 
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Figure 18    Undercarboxylated osteocalcin (ucOC) at Visit 1 and 2 
 
Figure 19    crosslaps (croosL) at Visit 1 and 2 
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To test significance of changes from Visit 1 to 2, Wilcoxon signed ranks test was performed 
(Table 6). 
 
Table 6   Weight, BMI, BG regulation parameters, HOMA indexes and total and undercarboxylated osteocalcin levels at Visit 
1 and 2 
  VISIT 1 VISIT 2 
p value 
  Mean Median Mean Median 
WEIGHT [Kg] 88.8 88.0 86.8 85.0 <0.001 
BMI [Kg/m2] 29.9 29.2 29.2 28.7 <0.001 
HbA1c [%] 8.5 8.0 6.9 6.5 <0.001 
FBG [mmol/L] 9.5 9.0 7.2 7.0 <0.001 
Ins [uU/L] 24.9 18.0 22.6 21.5 0.693 
HOMA B% 19.8 15.0 28.0 23.8 0.001 
HOMA S% 259.8 218.9 312.1 188.7 0.606 
HOMA-IR 0.6 0.5 0.5 0.5 0.563 
TOC [ug/L] 12.2 11.8 12.6 12.9 0.101 
ucOC [ng/mL] 
ucOC/TOC 
2.3 
0.14 
2.0 
0.11 
1.5 
0.09 
1.4 
0.13 
0.465 
0.575 
 
 
There was a significant change in weight, BMI, HbA1c, FBG and HOMA%B but no HOMA 
IR (estimate of insulin resistance). Mean ucOC was lower at Visit 2, however the difference 
did not reach significance as well as the difference of ucOC/TOC ratio. 
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To test a possible association of difference in HbA1c and undercaboxylated osteocalcin 
(ucOC) levels between Visits 1 and 2 (Figure 20), Spearman rho test was performed. 
Correlation coefficient was -0.177; nonsignificant (p=0.431) 
 
 
 
 
Figure 20  Scatter plot of change in HbA1c vs ucOC between Visits 1 and 2 
 
Median drop in HbA1c between visits 1 and 2 was 1.6%. Median ucOC level in patients with 
a drop higher than 1.6% was 2.35 ng/mL: no significantly (p=0.22) higher than in those with 
a lower drop in HbA1c: 1.21 ng/mL 
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Also, to test a possible association of difference in FBG and undercaboxylated osteocalcin 
(ucOC) levels between Visits 1 and 2 (Figure 21), Spearman rho test was performed. 
Correlation coefficient was -0.221; nonsignificant (p=0.324) 
 
Figure 21  Scatter plot of change in FBG vs ucOC between Visits 1 and 2 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Spearman rho test was performed to test a possible association of difference in BMI and 
undercaboxylated osteocalcin (ucOC) levels between Visits 1 and 2 (Figure 22). Correlation 
coefficient was 0.216; nonsignificant (p=0.334). 
 
Figure 22  Scatter plot of change in BMI vs ucOC between Visits 1 and 2 
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6 DISCUSSION 
To our knowledge, this study is the first prospective study planned for monitoring the level of 
the two forms of osteocalcin, TOC and ucOC, in type 2 diabetics, before and after three-
month improvement of blood glucose control without antidiabetic therapy in a European 
population. 
Even though we achieved significant change in weight, BMI, HbA1c, FBG and HOMA%B 
(rough estimate of beta cell function) but not in HOMA IR and HOMA%B (estimate of 
insulin resistance), we did not find significant change in TOC and ucOC levels with BG 
levels improvement in three months of follow up with only life style change and no 
medication for diabetes. Total and undercarboxylated osteocalcin levels did not correlate with 
BMI, insulin or HOMA IR indexes. The only significant correlation was a negative one 
between BMI and ucOC level at first Visit.  
Mean ucOC was lower at Visit 2, however the difference did not reach significance as well as 
the difference of ucOC/TOC ratio. We tested a possible association of difference in HbA1c 
and ucOC levels between Visits 1 and 2 and we found a nonsignificant correlation. 
The animal model study conducted by Lee et al. found that OC gene knockout (OC
_/_ 
mice) 
could lead to elevated blood glucose and insulin levels, as well as decreased insulin 
sensitivity
25
, suggesting that OC could in turn regulate glucose metabolism. In the former 
studies on OC in humans, the total levels of OC were reported lower in patients with T2D and 
serum OC would increase after blood glucose was controlled
28
. After the discovery of the 
endocrine properties of ucOC in mice, it was necessary to evaluate the relationship between 
ucOC and glucose metabolism in humans. Does ucOC have the similar function in human 
body? The answer is uncertain, the evidence has been only in part confirmed in humans, 
results remain conflicting and most of these reports were based on retrospective and cross-
sectional analyses of studies that were not specifically designed to determine the relationship 
between osteocalcin and glucose metabolism. To our knowledge, in all studies with type 2 
diabetics one of the confounding factors in this issue might be the treatment with antidiabetic 
drugs. 
The first direct evidence in humans showing that OC regulates energy metabolism might be 
provided by Confavreux et al.
47
. Two patients undergoing surgical resection of an OC-
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producing osteoid osteoma have been described. One day after surgery, ucOC levels had 
decreased and serum glucose levels had strongly increased
48
. 
Most previous studies have already demonstrated that TOC levels correlate with fasting blood 
glucose and HbA1c levels
34, 35, 38
. Indeed, only few studies measured both the total and the 
undercarboxylated form of osteocalcin, which precludes definitive conclusions regarding the 
role of osteocalcin carboxylation in glucose metabolism. While some did not determine an 
association between ucOC and the measures of glycaemia
49
, another study found inverse 
correlation of ucOC only with fasting blood glucose
50
.  
In our study, from two forms of OC, only ucOC was slightly lower at the end, but did not 
reach significance as well as the difference of ucOC/TOC ratio. Patients reaching higher drop 
in HbA1c tend to have higher basal ucOC levels, however this also was not significant. 
Changes in ucOC between visit 1 and 2, did not correlate with the change in HbA1c or FBG. 
Kanazawa et al.
41
 followed the level of TOC and ucOC in type 2 Japanese diabetic patients 
before and after a month of improvement of blood glucose control. They found an increase of 
serum TOC, unsignificant increase of serum ucOC and decrease of ucOC/OC ratio. However, 
unlike in present study, patients (n=50) were on various antidiabetics.   
A possible explanation for the lack of concordance among these studies could be in part 
related to the current limitations in the measurement of circulating undercarboxylated 
osteocalcin levels and the lack of standardization among the different techniques
51
. 
Some studies on Caucasian and Asian populations
34, 36, 52
 showed that TOC level was 
significantly negatively correlated with fasting blood glucose, fasting insulin, and HOMA-IR. 
A Chinese study showed that TOC was not related to HOMA-IR in type 2 diabetics
39
. Mori et 
al. also found no significant correlation of ucOC with insulin resistance in type 2 diabetic 
patients
53
. Some studies found a positive correlation of osteocalcin with only HOMA of beta-
cell function (HOMA%B) in diabetic patients, before and after glycaemic control
39, 54
.  
A recent longitudinal study in elderly men, including those with diabetes, showed that the 
increase in ucOC levels was associated with improvements in the HOMA-IR, and this 
association was limited to subjects who were not treated with antidiabetic drugs
55
. Therefore, 
aberrant glucose metabolism, drug interventions or both may make it more difficult to 
interrupt the correlation between ucOC levels and insulin resistance. In this regard, Iki et al. 
clearly showed a significant inverse association between ucOC levels and the HOMA-IR in 
community-based population without apparent health problems
56
. 
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In our study, there was a significant change only in HOMA%B but not HOMA IR, and it did 
not correlate with TOC or ucOC.  
Some studies demonstrated that TOC negatively correlated with BMI
38, 49  
as for ucOC are 
reported no correlations with BMI
49
. In our study, we observed a decrease in BMI between 
Visit 1 and 2 with only life style change (diet and exercise) and no antidiabetic medication, 
but not a significant correlation of BMI change with the change in ucOC level.  
In our study, ucOC was slightly lower at the end, but there was no association with a TOC or 
Crosslaps, which might suggest no biological association of this parameter with bone 
metabolism. 
Mouse genetic data have established osteocalcin as a positive regulator of insulin production 
and insulin sensitivity. There is also a significant body of clinical correlations between low 
levels of osteocalcin and various measures associated with diabetes. These combined data 
suggest that raising serum osteocalcin levels could be a novel therapeutic avenue to prevent 
or treat diabetes. At the present time, the therapeutic potential of osteocalcin has only been 
tested in vivo in two mouse models of metabolic dysregulation. In a first set of experiments, 
recombinant osteocalcin or vehicle was infused subcutaneously into mice fed a high-fat diet. 
The mice receiving osteocalcin gained significantly less weight, were less glucose intolerant 
and were less insulin resistant than mice receiving vehicle
33
. Osteocalcin-treated mice also 
showed normalised triacylglycerol levels. In a second experiment, mice were pre-treated with 
gold thioglucose, a chemical destroying neurons of the arcuate nuclei that control satiety, and 
thus developed hyperphagia. While vehicle-treated mice gained weight and became glucose 
intolerant and insulin resistant, osteocalcin-treated mice remained normoglycaemic and had 
normal response to glucose and insulin 
33
. Although of very limited scope, the successful 
outcome of these studies is a strong incentive to further evaluate the therapeutic potential of 
osteocalcin. 
Strengths of the study: treatment-naive newly diagnosed patients who are not prescribed any 
blood glucose lowering medications. 
Limitations of the study: small number of participants.  
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There is a paucity of published data on undercarboxylated osteocalcin levels in humans and 
their possible changes in diabetes, so the estimated number might be too low to reveal the 
trend.  
Basic of glucose regulation is in any case a diet and exercise intervention or the life style 
change, which is considered the basic treatment. For this recommendation there is high-
quality evidence. The effectiveness of non-pharmacological therapy is reflected in the fact 
that it is capable of lowering the HbA1c by about 2 %
57
. 
When the life style change cannot achieve good glucose regulation (desirable HbA1c), the 
treatment begins with metformin for which there is a strong recommendation based on 
evidence of high quality. The ADA and the German Diabetes Society recommend to 
immediately begin the treatment with metformin at diagnosis point unless a contraindication 
or intolerance for metformin exists (Figure 1). If a contraindication or intolerance for 
metformin does exist, the therapy is recommended with a substance that is approved for 
monotherapy (acarbose, PPAR- γ ligands, repaglinide, sulphonylurea (alphabetical list)), if 
the HbA1c is still >6.5% after 3-6 months of non-pharmacological treatment.  
The guidelines of the International Diabetes Federation (IDF) distinguish normal and 
alternative approach that does not include the initial phase of pharmacotherapy treatment. 
First-line treatment is only a basic treatment, which involves a lifestyle change (Figure 2). 
In our study, a considerable number of patients achieved the target HbA1c (32 patients at 
Visit 2 had HbA1c <7%) without introducing drug therapy, which challenges the current 
guidelines – to prescribe medication from the very beginning. 
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7 CONCLUSIONS 
The present study measured two forms of osteocalcin, TOC and ucOC, in newly diagnosed 
type 2 diabetic patients, before and after three-month improvement of blood glucose control 
without antidiabetic therapy. 
Even though we achieved significant change in weight, BMI, HbA1c, FBG and HOMA%B 
(rough estimate of beta-cell function) but not in HOMA IR or HOMSA%S (estimates of 
insulin resistance), we did not find a significant change in TOC and ucOC levels after three 
months. Median ucOC was lower at Visit 2, however the difference did not reach 
significance.  
Total and undercarboxylated osteocalcin levels did not correlate with insulin, HOMA IR 
indexes or BMI.  
In our study, ucOC was slightly lower at the end, but there was no association with TOC or 
crosslaps, which shows that it is not related to bone metabolism. 
Although this study did not show changes in osteocalcin levels with blood glucose regulation, 
it does not exclude them. Sample size, which was calculated from the data from published 
studies, might be too low. Larger studies possibly with different design are warranted.  
The hypothesis of an association between skeleton and energy metabolism could be 
supported in recent years by experiments in mouse models and by some, but not all, mainly 
observational data from a modest number of clinical studies. The exact function of 
osteocalcin, especially its undercarboxylated form in metabolic pathways, remains to be 
clarified. 
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8 SAŽETAK (ABSTRACT IN CROATIAN) 
Uvod: Od 2007. je objavljeno nešto in vitro i in vivo ispitivanja koja ukazuju na moguću 
ulogu podkarboksiliranog osteokalcina (ucOC) u energetskom metabolizmu i glukoregulaciji.  
Ciljevi: Cilj studije je ispitati odnos ucOC i kontrole glukoze u plazmi (GUP) u osoba s 
novootkrivenom šećernom bolešću tipa 2 i promjenu s poboljšanjem glukoregulacije. 
Pacijenti i metode: Pedeset sedam osoba s novootkrivenom šećernom bolešću tipa 2 je dobilo 
savjetovanje o promjeni stila života, nije prepisana medikamentozna terapija za kontrolu 
GUP na pregledu 1. Zaklučni pregled - 2 je bio tri mjeseca kasnije. Uzorci za određivanje 
parametara glukoregulacije i koštane pregradnje su uzeti na pregledu 1 i 2.  
Rezultati: Četrdeset sedam ispitanika je kompletiralo ispitivanje. Trideset dvoje (56%) 
ispitanika je postiglo ciljnu razinu HbA1c (≤7%). Nije uočena povezanost ucOC sa HbA1c i 
GUP. HbA1c i GUP su se značajno promijenili (median 8,0 na 6,5%; 9,0 na 7,0 mmol/L 
resp.; Wilcoxon signed rank test p<0,001), ucOC je u drugoj posjeti bio neznačajno niži (2,0 
na 1,4 mcg/L; p=0,465). Nije uočena povezanost razlika HbA1c i ucOC između 1. i 2. 
posjete. Indeks HOMA%B, no ne i HOMA IR, je pokazao značajnu promjenu, bez 
povezanosti s ucOC.  
Zaključak: ovo ispitivanje nije dokazalo povezanost regulacije glikemije i razine ucOC, 
međutim niti je isključuje, pa su potrebna daljnja ispitivanja. Činjenica da je čak 56% 
pacijenata postiglo ciljnu glukoregulaciju po HbA1c je izazov većini današnjih smjernica za 
glukoregulaciju. 
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9 ABSTRACT 
Introduction: From year 2007. in vitro and in vivo studies have suggested a role of 
undercarboxylated osteocalcin (ucOC) in glucose and energy metabolism.  
Aims: The aim of the study was to investigate the relationship of ucOC level and blood 
glucose (BG) control in newly diagnosed type 2 diabetes and its change with BG control 
improvement. 
Subjects and methods: Fifty seven newly diagnosed type 2 diabetic patients had a 
consultation about life style changes on visit 1, no BG regulation medication was prescribed. 
The final visit (2) was three months later.  Samples for parameters of BG metabolism and 
bone turnover were collected on visit 1 and 2. 
Results: Forty seven patients completed the study. Thirty two (56%) patients reached the 
target HbA1c (≤7%). No correlation of ucOC and HbA1c and FBG was observed. Median 
HbA1c and FBG changed significantly (8.0 to 6.5%; 9.0 to 7.0 mmol/L resp.; Wilcoxon 
signed rank test p<0.001), ucOC was slightly but not significantly lower (2.0 to 1.4 mcg/L; 
p=0.465). No correlation between differences in HbA1c and ucOC between Visits 1 and 2 
was revealed. There was a significant change in HOMA%B but not HOMA IR, not correlated 
to ucOC.  
Conclusion: This study failed to prove the relationship between blood glucose regulation and 
ucOC level. However, it does not exclude it, so further research is needed. The fact that as 
much as 56% patients achieved the target HbA1c with no medication, challenges most BG 
control guidelines. 
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